Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Wilken, Jason A ^a   Webster, Kristy T ^b,c   Maihle, Nita J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; TRASTUZUMAB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM CARE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 77953464877     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-7     Document Type: Article

References (60)

1. Cancer statistics, 2009. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun, CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
2. Ovarian cancer: front-line standard treatment in 2008. PA Vasey, Ann Oncol 2008 19 Suppl 7 22ii61 66 10.1093/annonc/mdn479 18790981
3. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. JM Lafky JA Wilken AT Baron NJ Maihle, Biochim Biophys Acta 2008 1785 232 265 18291115
4. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. J Konner RJ Schilder FA DeRosa SR Gerst WP Tew PJ Sabbatini ML Hensley DR Spriggs CA Aghajanian, Gynecol Oncol 2008 110 140 145 10.1016/j.ygyno.2008. 04.018 18554700
5. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. AA Secord JA Blessing DK Armstrong WH Rodgers Z Miner MN Barnes G Lewandowski RS Mannel, Gynecol Oncol 2008 108 493 499 10.1016/j.ygyno.2007.11.029 18191993
6. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. RJ Schilder HB Pathak AE Lokshin RW Holloway RD Alvarez C Aghajanian H Min K Devarajan E Ross CW Drescher AK Godwin, Gynecol Oncol 2009 113 21 27 10.1016/j.ygyno.2008.12.003 19162309
7. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. MV Seiden HA Burris U Matulonis JB Hall DK Armstrong J Speyer JD Weber F Muggia, Gynecol Oncol 2007 104 727 731 10.1016/j.ygyno.2006. 10.019 17126894
8. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. RJ Schilder MW Sill X Chen KM Darcy SL Decesare G Lewandowski RB Lee CA Arciero H Wu AK Godwin, Clin Cancer Res 2005 11 5539 5548 10.1158/1078-0432.CCR-05-0462 16061871
9. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. AN Gordon N Finkler RP Edwards AA Garcia M Crozier DH Irwin E Barrett, Int J Gynecol Cancer 2005 15 785 792 10.1111/j.1525-1438.2005.00137.x 16174225
10. Cardiac toxicity of ErbB2-targeted therapies: what do we know? EA Perez, Clin Breast Cancer 2008 8 Suppl 3 114 120 10.3816/CBC.2008.s.007 18777950
11. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark, N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122 16236738
12. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. MA Bookman KM Darcy D Clarke-Pearson RA Boothby IR Horowitz, J Clin Oncol 2003 21 283 290 10.1200/JCO.2003.10.104 12525520
13. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. GF Fleming NJ Meropol GL Rosner DR Hollis WE Carson III M Caligiuri J Mortimer K Tkaczuk R Parihar RL Schilsky MJ Ratain, Clin Cancer Res 2002 8 3718 3727 12473581
14. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich MF Press, Science 1989 244 707 712 10.1126/science. 2470152 2470152
15. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. M Narayan JA Wilken LN Harris AT Baron KD Kimbler NJ Maihle, Cancer Res 2009 69 2191 2194 10.1158/0008-5472.CAN-08-1056 19276389
16. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Y Nagata KH Lan X Zhou M Tan FJ Esteva AA Sahin KS Klos P Li BP Monia NT Nguyen GN Hortobagyi MC Hung D Yu, Cancer Cell 2004 6 117 127 10.1016/j.ccr.2004.06.022 15324695
17. Herceptin: mechanisms of action and resistance. R Nahta FJ Esteva, Cancer Lett 2006 232 123 138 10.1016/j.canlet.2005.01.041 16458110
18. Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines. K Stromberg TJt Collins AW Gordon CL Jackson GR Johnson, Cancer Res 1992 52 341 347 1309440
19. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin. G Cassinelli C Lanzi T Pensa RA Gambetta G Nasini G Cuccuru M Cassinis G Pratesi D Polizzi M Tortoreto F Zunino, Biochem Pharmacol 2000 59 1539 1547 10.1016/S0006-2952(00)00278-1 10799650
20. ErbB receptor expression and growth response to heregulin beta 1 in five ovarian carcinoma lines. JC Pegues B Kannan K Stromberg, Int J Oncol 1999 14 1169 1176 10339675
21. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. M Hermes W Schormann M Brulport K Uhlemann F Lupatsch LC Horn A Schumann C Allgaier M Weishaupt K Engeland GA Muller J Mossner A Bauer IB Schiffer S Gebhard M Schmidt E Lausch D Prawitt C Wilhelm JG Hengstler, Br J Cancer 2008 98 1525 1532 10.1038/sj.bjc.6604318 18454161
22. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. AR Tan DF Moore M Hidalgo JH Doroshow EA Poplin S Goodin D Mauro EH Rubin, Clin Cancer Res 2006 12 6517 6522 10.1158/1078-0432.CCR-06-0705 17065274
23. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. MH Cohen GA Williams R Sridhara G Chen R Pazdur, Oncologist 2003 8 303 306 10.1634/theoncologist.8-4-303 12897327
24. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. HA Burris III HI Hurwitz EC Dees A Dowlati KL Blackwell B O'Neil PK Marcom MJ Ellis B Overmoyer SF Jones JL Harris DA Smith KM Koch A Stead S Mangum NL Spector, J Clin Oncol 2005 23 5305 5313 10.1200/JCO.2005.16.584 15955900
25. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. M Hidalgo LL Siu J Nemunaitis J Rizzo LA Hammond C Takimoto SG Eckhardt A Tolcher CD Britten L Denis K Ferrante DD Von Hoff S Silberman EK Rowinsky, J Clin Oncol 2001 19 3267 3279 11432895
26. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. C Bengala S Bettelli F Bertolini S Salvi S Chiara C Sonaglio L Losi N Bigiani G Sartori C Dealis N Malavasi R D'Amico G Luppi B Gatteschi A Maiorana PF Conte, Ann Oncol 2008 19095777
27. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. S Benvenuti A Sartore-Bianchi F Di Nicolantonio C Zanon M Moroni S Veronese S Siena A Bardelli, Cancer Res 2007 67 2643 2648 10.1158/0008-5472.CAN-06-4158 17363584
28. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. M Frattini P Saletti E Romagnani V Martin F Molinari M Ghisletta A Camponovo LL Etienne F Cavalli L Mazzucchelli, Br J Cancer 2007 97 1139 1145 10.1038/sj.bjc.6604009 17940504
29. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. CS Karapetis S Khambata-Ford DJ Jonker CJ O'Callaghan D Tu NC Tebbutt RJ Simes H Chalchal JD Shapiro S Robitaille TJ Price L Shepherd HJ Au C Langer MJ Moore JR Zalcberg, N Engl J Med 2008 359 1757 1765 10.1056/NEJMoa0804385 18946061
30. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PS Hammerman PA Janne BE Johnson, Clin Cancer Res 2009 15 7502 7509 10.1158/1078-0432.CCR-09-0189 20008850
31. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. JA Engelman PA Janne, Clin Cancer Res 2008 14 2895 2899 10.1158/1078-0432.CCR-07-2248 18483355
32. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. S Makhija LC Amler D Glenn FR Ueland MA Gold DS Dizon V Paton CY Lin T Januario K Ng A Strauss S Kelsey MX Sliwkowski U Matulonis, J Clin Oncol 2010 28 1215 1223 10.1200/JCO.2009.22.3354 19901115
33. HER2 status and benefit from adjuvant trastuzumab in breast cancer. S Paik C Kim N Wolmark, N Engl J Med 2008 358 1409 1411 10.1056/NEJMc0801440 18367751
34. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. KE Longva NM Pedersen C Haslekas E Stang IH Madshus, Int J Cancer 2005 116 359 367 10.1002/ijc.21015 15800944
35. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. H Asanuma T Torigoe K Kamiguchi Y Hirohashi T Ohmura K Hirata M Sato N Sato, Cancer Res 2005 65 11018 11025 10.1158/0008-5472.CAN-05-0491 16322251
36. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. MS Gordon D Matei C Aghajanian UA Matulonis M Brewer GF Fleming JD Hainsworth AA Garcia MD Pegram RJ Schilder DE Cohn L Roman MK Derynck K Ng B Lyons DE Allison DA Eberhard TQ Pham RC Dere BY Karlan, J Clin Oncol 2006 24 4324 4332 10.1200/JCO.2005.05.4221 16896006
37. HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation. A Jain E Penuel S Mink J Schmidt A Hodge K Favero C Tindell DB Agus, Cancer Res 2010 20160029
38. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. M Tuefferd J Couturier F Penault-Llorca A Vincent-Salomon P Broet JP Guastalla D Allouache M Combe B Weber E Pujade-Lauraine S Camilleri-Broet, PLoS One 2007 2 1138 10.1371/journal.pone.0001138 17987122
39. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. SL Spencer S Gaudet JG Albeck JM Burke PK Sorger, Nature 2009 459 428 432 10.1038/nature08012 19363473
40. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. M Barok J Isola Z Palyi-Krekk P Nagy I Juhasz G Vereb P Kauraniemi A Kapanen M Tanner G Vereb J Szollosi, Mol Cancer Ther 2007 6 2065 2072 10.1158/1535-7163.MCT-06-0766 17620435
41. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. M Barok M Balazs P Nagy Z Rakosy A Treszl E Toth I Juhasz JW Park J Isola G Vereb J Szollosi, Cancer Lett 2008 260 198 208 10.1016/j.canlet.2007.10.043 18096313
42. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. G von Minckwitz A du Bois M Schmidt N Maass T Cufer FE de Jongh E Maartense C Zielinski M Kaufmann W Bauer KH Baumann MR Clemens R Duerr C Uleer M Andersson RC Stein V Nekljudova S Loibl, J Clin Oncol 2009 27 1999 2006 10.1200/JCO.2008.19.6618 19289619
43. Sensitization of breast cancer cells to radiation by trastuzumab. K Liang Y Lu W Jin KK Ang L Milas Z Fan, Mol Cancer Ther 2003 2 1113 1120 14617784
44. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. AM Tari SJ Lim MC Hung FJ Esteva G Lopez-Berestein, Oncogene 2002 21 5224 5232 10.1038/sj.onc.1205660 12149644
45. Cancer. Addiction to oncogenes - the Achilles heal of cancer. IB Weinstein, Science 2002 297 63 64 10.1126/science.1073096 12098689
46. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. SV Sharma MA Fischbach DA Haber J Settleman, Clin Cancer Res 2006 12 4392s 4395s 10.1158/1078-0432.CCR-06-0096 16857816
47. Oncogenic shock: turning an activated kinase against the tumor cell. SV Sharma J Settleman, Cell Cycle 2006 5 2878 2880 17218790
48. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. C Cao S Lu A Sowa R Kivlin A Amaral W Chu H Yang W Di Y Wan, Cancer Lett 2008 266 249 262 10.1016/j.canlet.2008.02.062 18400375
49. Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy. CJ Tai HY Lo CH Hsu CJ Tai WM Liu, Gynecol Oncol 2006 101 184 185 10.1016/j.ygyno.2005.11.043 16413601
50. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. S Abuharbeid J Apel M Sander B Fiedler M Langer ML Zuzarte F Czubayko A Aigner, Biochem Biophys Res Commun 2004 321 403 412 10.1016/j.bbrc.2004.06.160 15358191 (Pubitemid 39055761)
51. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. M Cuello SA Ettenberg AS Clark MM Keane RH Posner MM Nau PA Dennis S Lipkowitz, Cancer Res 2001 61 4892 4900 11406568
52. Neuregulin expression, function, and signaling in human ovarian cancer cells. LM Gilmour KG Macleod A McCaig JM Sewell WJ Gullick JF Smyth SP Langdon, Clin Cancer Res 2002 8 3933 3942 12473609
53. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. GD Lewis I Figari B Fendly WL Wong P Carter C Gorman HM Shepard, Cancer Immunol Immunother 1993 37 255 263 10.1007/BF01518520 8102322
54. [Effect of trastuzumab on tumor cell lines shedding high or low level of HER-2 ECD]. CY Liu W Yang JF Li SL Sun CC Shou, Zhonghua Zhong Liu Za Zhi 2007 29 101 105 17645842
55. Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. C Marth MV Cronauer W Doppler D Ofner A Ullrich G Daxenbichler, Int J Cancer 1992 50 64 68 10.1002/ijc.2910500114 1370227
56. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. JA Menendez L Vellon R Lupu, Int J Gynecol Cancer 2006 16 219 221 10.1111/j.1525-1438.2006. 00297.x 16445636
57. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. S Palm T Back I Claesson A Danielsson J Elgqvist S Frost R Hultborn H Jensen S Lindegren L Jacobsson, Int J Radiat Oncol Biol Phys 2007 69 572 579 17869670
58. Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression. G Pfeiler F Horn C Lattrich S Klappenberger O Ortmann O Treeck, Oncol Rep 2007 18 1305 1309 17914589
59. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. C Scheffold M Kornacker YC Scheffold CH Contag RS Negrin, Cancer Res 2002 62 5785 5791 12384539
60. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. HM Shepard GD Lewis JC Sarup BM Fendly D Maneval J Mordenti I Figari CE Kotts MA Palladino Jr A Ullrich D Slamon, J Clin Immunol 1991 11 117 127 10.1007/BF00918679 1679763